

Gilboa Therapeutics

- **Investment Rational:** Gilboa Tx is a pre-clinical stage biotech company developing a breakthrough T cell therapy for solid cancers, that overcome the inherent limitations of CAR T cells. These novel engineered T-cells, called **SolidT**, show effective and specific cytotoxicity only towards tumor cells, sparing normal tissues expressing low antigen levels, thus providing a favorable safety profile.
- **Core Technology:** Peripheral blood T cells engineered with Gilboa's novel receptor, based on the high affinity FcγRI scaffold, allowing T-cells to target solid tumor cells using antibody intermediates. This breakthrough technology manifests remarkable killing abilities against solid tumors in mouse models with an unprecedented safety profile.
- **Product Profile/Pipeline:** Gilboa Tx is developing an extensive pipeline, including off-the-shelf **SolidT** based on engineered γ/δ T cells, next generation **SolidT** that target HER2 +1 tumors, and develop new combinations with proprietary antibodies to target diseases with urgent unmet medical need.
- ⊖ **What's Next:** Gilboa Tx is now raising Series A financing round for clinical proof of concept